Gut bacterial azoreductase (AzR)

Gut bacterial azoreductases are a diverse group of enzymes produced by anaerobic bacteria within the human intestinal tract, such as members of the genera Bacteroides, Clostridium, and Bifidobacterium (PMID: 17433413). These enzymes are specialized in the reductive cleavage of azo linkages (-N=N-), a process that typically requires electron donors like NAD(P)H and often involves flavin mononucleotide (FMN) as a cofactor (PMID: 21812504). Their primary therapeutic significance lies in the site-specific delivery of anti-inflammatory drugs to the colon, particularly for treating inflammatory bowel diseases like ulcerative colitis and Crohn's disease (PMID: 15554240). Prodrugs such as sulfasalazine and balsalazide remain intact through the upper gastrointestinal tract and are only activated when they reach the colon, where bacterial azoreductases cleave the azo bond to release the active agent, 5-aminosalicylic acid (5-ASA). This localized activation maximizes the drug concentration at the site of inflammation while minimizing systemic exposure and associated toxicity. However, the therapeutic efficacy of these prodrugs can be influenced by variations in the individual's gut microbiota composition, which may be altered by diet, antibiotics, or disease states (PMID: 25614877). Additionally, these enzymes are involved in the metabolism of dietary azo dyes, which can occasionally result in the formation of potentially harmful aromatic amines.

Other names

AzoreductaseAzo reductaseNAD(P)H:azo dye oxidoreductaseFMN-dependent azoreductaseDiazo-reductase

Reductive cleavage of the azo linkage (-N=N-) in prodrugs, releasing the active therapeutic moiety (typically 5-aminosalicylic acid) specifically in the colon.